TearClear has raised $34.8m to date to fund an anti-preservative eye drop technology invented at University of Florida.
TearClear, a US-based eye disease therapy developer founded out of University of Florida, has raised $22m of series B funding from investors including venture capital fund Visionary Ventures.
The deal was rounded off by investment partnership Flying L Partners and venture capital and private equity firm Bluestem Capital.
Founded in 2015, TearClear has devised an approach for delivering topical eyedrops while removing preservatives to prevent them from reaching the ocular surface, reducing the likelihood of harmful side-effects such…
